Asymmetric dimethylarginine (ADMA) and acute vascular events

Clinica Chimica Acta

Volumn 348, Issue 1-2, 2004, Pages 9-17

  Valkonen, Veli Pekka ^a   Laaksonen, Reijo ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; ATORVASTATIN; CITRULLINE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOLIC ACID; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PRAVASTATIN; PYRIDOXAL 5 PHOSPHATE; SIMVASTATIN; SUPEROXIDE; TETRAHYDROBIOPTERIN; VITAMIN B GROUP;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); HUMAN; HYPERLIPIDEMIA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; STROKE;

ACUTE DISEASE; ANGINA PECTORIS; ARGININE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; HUMANS; MYOCARDIAL INFARCTION;

ANGINA;

EID: 4444366771     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.05.020     Document Type: Review

References (73)

1. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 83:1986;1946-1952
2. Vita J.A., Treasure C.B., Nabel E.G., McLenachan J.M., Fish R.D., Yeung A.C., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497
3. Creager M.A., Cooke J.P., Mendelsohn M.E., Gallagher S.J., Coleman S.M., Loscalzo J., et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86:1990;228-234
4. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects related to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24:1994;1468-1474
5. Böger B.H., Bode-Böger S.M., Thiele W., Creutzig A., Alexander K., Frölich J.C. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32:1998;1336-1344
6. G-dimethyl- arginine, N-epsilon-mono-, di, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 245:1970;5751-5758
7. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 339:1992;572-575
8. Zelis R., Mason D.T., Braunwald E. A comparison to the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J. Clin. Invest. 47:1968;960-970
9. Cannon C.R., McGoon M.D., Holmes D.R. Jr., Lerman A. Altered coronary endothelial function in a patient with asymptomatic left ventricular dysfunction. Int. J. Cardiol. 53:1996;147-151
10. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516
11. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97:1996;2601-2610
12. Park J.B., Charbonneau F., Schiffrin E.L. Correlation of endothelial function in large and small arteries in human essential hypertension. J. Hypertens. 19:2001;415-420
13. Böger R.H., Bode-Böger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20:2000;1557-1564
14. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 358:2001;2113-2117
15. Ghosh S.K., Paik W.K., Kim S. Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-spesific enzymes. J. Biol. Chem. 263:1988;19024-19033
16. Millward D.J. Protein turnover in skeletal muscle. II. The effect of starvation and a protein-free diet on the synthesis and catabolism of skeletal muscle proteins in comparison to liver. Clin. Sci. 39:1970;591-603
17. Goldberg A.L., St John A.C. Intracellular protein degradiation in mammalian and bacterial cells: part 2. Annu. Rev. Biochem. 45:1976;747-803
18. Dice J.F., Walker C.D. Protein degradation in metabolic and nutritional disorders. Ciba Found. Symp. 75:1979;331-350
19. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264:1989;10205-10209
20. Leiper J.M., Santa Maria J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethyl-amoninohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem. J. 343:1999;209-214
21. Tran C.T.L., Leiper J.M., Vallance P. The DDAH/ADMA/NOS pathway. Atherosclerosis. S4:2003;33-40
22. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119(8):1996 (Dec);1533-1540
23. Leiper J., Murray-Rust J., McDonald N., Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc. Natl. Acad. Sci. U.S.A. 99:2002;13527-13532
24. Sydow K., Münzel T. ADMA and oxidative stress. Atherosclerosis. 4:2003;41-51. [Suppl.]
25. Drexler H., Zeiher A.M., Mainzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550
26. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 98:1998;1842-1847
27. Ceremuzynski L., Chamiec T., Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. J. Cardiol. 80:1997;331-333
28. Gage J.E., Hess O.M., Murakami T., Ritter M., Grimm J., Krayenbuehl H.P. Vasoconstriction of stenotic arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 73:1986;865-876
29. Zeiher A.M., Krause T., Schächinger V., Minners J., Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 91:1995;2345-2352
30. Piatti P.M., Fragasso G., Monti L.D., Setola E., Lucotti P., Fermo I., et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation. 107:2003;429-436
31. Hori T., Matsubara T., Ishibari T., Ozaki K., Tsuchida K., Mezaki T., et al. Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ. J. 67:2003;305-311
32. Ceremuzynski L., Chamiec T., Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. J. Cardiol. 80:1997;331-333
33. Walker H.M., McGing E., Fisher I., Böger R.H., Bode-Böger S.M., Jackson G., et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J. Am. Coll. Cardiol. 38:2001;499-505
34. Parker J.O., Parker J.D., Caldwell R.W., Farrell B., Kaesemeyer W.H. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J. Am. Coll. Cardiol. 39:2002;1199-1203
35. Abou-Mohammed G.M., Kaesemeyer W.H., Caldwell R.B., Caldwell R.W. Role of L-arginine in the vascular actions and development of tolerance to nitroglyserin. Br. J. Pharmacol. 130:2000;211-218
36. Valkonen V.-P., Päivä H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 358:2001;2127-2128
37. Böger R.H., Lenzen H., Hanefeld C., et al. Asymmetric dimethylarginine: an endogenous inhibitor of NO synthase is a predictor of the risk for coronary heart disease - results of the multicenter CARDIAC study [abstract]. Circulation. 108(Suppl 4):2003;256-257
38. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur. Heart J. 24:2003;1912-1919
39. Vallance P. Importance of asymmetric dimethylarginine in cardiovascular risk. Lancet. 358:2001;2096-2097
40. Zoccali C., Mallamaci R., Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J. Am. Soc. Nephrol. 15:2004;S77-S80
41. Yoo J.-H., Lee S.-C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 158:2001;425-430
42. Yu X.J., Li Y.J., Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci. 54:1994;753-758
43. Bode-Böger S.M., Böger R.H., Kienke S., Junker W., Frolich J.C. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Res. Commun. 219:1996;598-603
44. Jang J.J., Ho H.-K.V., Kwan H.H., Fajardo L.F., Cooke J.P. Angiogenesis is impaired by hypercholesterolemia. Role of asymmetric dimethylarginine. Circulation. 102:2000;1414-1419
45. Päivä H., Laakso J., Lehtimäki T., Isomustajärvi M., Ruokonen I., Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 41(2):2003;219-222
46. Eid H.M., Eritsland J., Larsen J., Arnesen J., Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis. 166(2):2003 (Feb);279-284
47. Cardinale C.P., Fard A., Eisenberg M.S., et al. Elevated plasma level of asymmetric dimethylarginine (ADMA) is associated with atherosclerotic disease of the thoracic aorta [abstract]. J. Am. Coll. Cardiol. 37(Suppl. A):2001;648A
48. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1451-1452
49. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor, a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146
50. Päivä H., Laakso J., Laine H., Laaksonen R., Knuuti J., Raitakari O.T. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J. Am. Coll. Cardiol. 40:2002;1241-1247
51. Fleck C., Schweitzer F., Arge K.E., Busch M., Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin. Chim. Acta. 336:2003;1-12
52. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487
53. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effects of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:1995;488-493
54. Järvisalo M.J., Toikka J.O., Vasankari T., Mikkola J., Viikari J.S., Hartiala J.J., et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis. 147:1999;237-242
55. Mullen M.J., Wright D., Donald A.E., Thorne S., Thomson H., Deanfield J.E. Atorvastatin but nor L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J. Am. Coll. Cardiol. 36:2000;410-416
56. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeicher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 103:2001;2885-2890
57. John S., Delles C., Jacobi J., Schlaich M.P., Schneider M., Schmitz G., et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J. Am. Coll. Cardiol. 37:2001;1351-1358
58. Bayerle-Eder M., Fuchsjager-Mayrl G., Sieder A., Polska E., Roden M., Stulnig T., et al. Effect of pravastatin on responsiveness to N-monomethyl-L-arginine in patients with hypercholesterolemia. Atherosclerosis. 160:2002;177-184
59. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33:1999;234-241
60. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082
61. Janatuinen T., Laakso J., Laaksonen R., Vesalainen R., Nuutila P., Lehtimaki T., et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc. Med. 8:2003;185-189
62. Boger R.H. Asymmetric dimethylarginine (ADMA) modulates endothelial function - therapeutic implications. Vasc. Med. 8:2003;149-151
63. O'Driscoll G., Green D., Rankin J., Stanton K., Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 100:1997;678-684
64. O'Driscoll G., Green D., Maiorana A., Stanton K., Colreavy F., Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 33:1999;1506-1511
65. Ito A., Egashira K., Narishige T., Muramatsu K., Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn. Circ. J. 65:2001;775-778
66. Ito A., Egashira K., Narishige T., Muramatsu K., Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ. J. 66:2002;811-815
67. Chen J.-W., Hsu N.-W., Wu T.-C., Lin S.-J., Chang M.-S. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90:2002;974-982
68. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentration in patients with type 2 diabetes. Metabolism. 51:2002;843-846
69. Chambers J.C., Ueland P., Obeid O.A., Wrigley J., Refsum H., Kooner J.S. Improved vascular endothelial function after oral B vitamins. An effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 102:2000;2479-2483
70. Tiefenbacher C.P., Bleeke T., Vahl C., Amann K., Vogt A., Kübler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation. 102:2000;2172-2179
71. Seteoguchi S., Mohri M., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J. Am. Coll. Cardiol. 38:2001;493-498
72. Sydow K., Schwedhelm E., Arakawa N., Bode-Boger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc. Res. 57:2003;244-252
73. Holven K.B., Haugstad T.S., Holm T., Aukrust P., Ose L., Nenseter M.S. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br. J. Nutr. 89:2003;359-363